Biogen Idec Seeks Oncology Pipeline Boost Through Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger with Conforma Therapeutics, valued at up to $250 mil., brings Biogen Idec a stable of developmental heat shock protein inhibitors.